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ABSTRACT
Peuler, Kevin M.S.B.M.E., Purdue University, May 2019. Modular Nanoparticles for
Selective Cell Targeting. Major Professor: Chien-Chi Lin.
Nanoparticles (NPs) are an emerging technology in biomedical engineering with
opportunities in diagnostics, imaging, and drug delivery. NPs can be prepared from a
wide range of organic and/or inorganic materials. They can be fabricated to exhibit
different characteristics for biomedical applications. The goal of this thesis was to
develop NPs with tunable surface properties for selective cell targeting. Specifically,
polyelectrolyte complexes composed of heparin (Hep, a growth factor binding gly-
cosaminoglycan) and poly-L-lysine (PLL, a homopolymeric lysine) were prepared via
a pulse sonication method. The Hep/PLL core NPs were further layered with addi-
tional Hep, tetrazine (Tz) modified Hep, or dextran sulfate (DS). The addition of Tz
handle on Hep backbone permitted easy modification of NP surface with norbornene
(NB) modified motifs/ligands, including inert poly(ethylene glycol) (PEG), cell ad-
hesive peptides (e.g., RGD), and/or fluorescent marker. Both Hep and DS coated
NPs could be readily internalized by J774A.1 monocytes/macrophages, whereas PE-
Gylated NPs effectively reduced cellular uptake/recognition. The versatility of this
NP system was further demonstrated by laying DS on the Hep/PLL NP surface.
DS-coated NPs were recognized by J774A.1 cells more effectively. Furthermore, DS-
layered NPs seemed to reduce IL-10 production on a per cell basis, suggesting that
these NPs could be used to alter polarization of macrophages.
1CHAPTER 1. INTRODUCTION
1.1 Biomedical Applications of Nanoparticles
Nanoparticle (NP) research is an accelerating field of study with promising work in
diagnostics, imaging, and drug delivery. In diagnostics, NPs are used in microarray
technology and acting as a biosensor for disease diagnosis. For example, You CC.
et al. created a protein detection array based on gold nanoparticles that quench
the fluorescence of the NP-bound probe (Figure 1.1A) [1]. The gold nanoparticle
quenches fluorescent polymers that are bound to the nanoparticle via electrostatic
interaction. Competitive binding by proteins release the fluorescent polymers. As
a consequence, the fluorescent polymers are no longer quenched by the nanoparticle
and can be quantitatively measured. An array composed of several nanoparticles with
differing binding motifs is capable of detecting different proteins based on fluorescence
signals.
Fig. 1.1: A) Schematic representation of protein detection with gold nanoparticles.
Gold nanoparticles quench green fluorescent strips, but upon binding with a protein
(blue analyte) are released and capable of being measured. B) Schematic
representation of a quantum dot tagged protein. C) Schematic representation of an
NP delivering a drug to a cell.
2For imaging, nano-scale quantum dots are used to label biological components,
such as cells and proteins (Figure 1.1B). Quantum dots are photostable, hence al-
lowing for real time monitoring of the movement of a biological component without
concerns of photo bleaching. Additionally, NPs are being developed as contrasting
agents for imaging applications, including nuclear magnetic resonance imaging (MRI),
computed tomography (CT), positron emission tomography (PET), and ultrasound.
The development of NPs for bio-imaging are with the intention to reduce the toxicity
of current contrasting agents and increase the imaging time.
In drug delivery, NPs can serve as a drug carrier with tissue-targeting capability,
which reduces off target adverse effects and the overall dosage of the drug delivered
to the body. NPs also offer a method of cellular uptake of materials that otherwise
would not be taken up, such as nucleic acids. Nucleic acids could be used for altering
cellular activity, but a designed method for uptake is needed to bring these molecules
into a cell, due to their very limited uptake by cells. For example, Lu et al. treated
doxorubicin resistant breast cancer cells with a nanoparticle composed of anti-ABCB1
small interfering RNA complexed with poly(ethylene glycol) (PEG) modified and L-
arginine oligo (alkylaminosiloxane) grafted PEI polyethyleneimine [2]. These NPs
downregulated ABCB1 protein, enhancing doxorubicin uptake, which ultimately lead
to increase cytotoxicity of the drug. Other biomedical applications of nanoparticles
are shown in table 1.1.
Depending on the application and desired characteristics, NPs can be fabricated
with organic materials (i.e. protein, polymer, lipids) or inorganic compounds (i.e.
gold, silica, iron oxide). For drug delivery and cellular targeting, polymers are par-
ticularly advantageous due their biocompatability, ease of modification, and a wide
range of natural and synthetic polymers are currently approved by the US Food and
Drug Administration (FDA) for biomedical applications.
3Table 1.1: Nanoparticle Materials and Fabrication Methods Employed for
Biomedical Applications.
1.1.1 Fabrication of Nanoparticles
Various molecular interactions have been employed to fabricate nanoparticles.
For example, amphiphilic molecules such as lipids are used to form liposomes and
micelles. Amphiphilic molecules are composed of both hydrophobic and hydrophilic
components. In solution, amphiphilic molecules can self-assemble into a monolayer or
bilayer, forming micelles and liposomes respectively. In aqueous solution, amphiphilic
molecules will minimize the interaction of the hydrophobic portion of the molecule
with the polar solvent. As shown in Figure 1.2, amphiphilic molecules will align
such that the hydrophilic portion of the molecules interacts with water while the
hydrophobic portions are sequestered, thereby reducing its interactions with water.
The hydrophobic portion can act as a cavity for carrying hydrophobic drugs, such
as paclitaxel. For example, Nosrati et al. loaded hydrophobic artemisinin into a
biodegradable micelle fabricated from a block copolymer composed of hydrophilic
PEG and hydrophobic polycaprolactone (PCL) for treating breast cancer [3]. Biotin
was conjugated to PEG and employed to target the over expressed biotin receptors on
breast cancer cells. In a BALBc tumor model, the biotintilated, artemisinin loaded
NPs were able to effectively target and significantly reduce tumor volume.
4Fig. 1.2: Schematic representation of lipids forming a micelle with the blue polar
head interfacing with polar solvent (i.e. water, acetonitrile, dimethyl sulfoxide) and
the orange hydrophobic tail sequestered. The hydrophobic cavity made by the
hydrophobic tails enable encapsulation of green hydrophobic drugs.
Hydrophobic interaction has also been employed for emulsion fabrication of nano-
particles. For example, a hydrophobic polymer can be dissolved in organic solvent
(e.g., dichloromethane, DCM) and emulsified in aqueous solution. After collecting the
NPs from the aqueous solution, DCM is allowed to evaporate and nano-scale polymer
spheres are recovered.
Electrostatic interactions are employed for fabrication of polyelectrolyte complex
(PEC) nanoparticles. The strong Coulombic force between negatively charged polyan-
ions and positively charged polycations complex the polymers together, forming PEC
NPs. Table 1.2 has some commonly used polymers for PEC NP fabrication. As
shown in Figure 1.3, PECs can be generated by simple agitation, vortex, or sonica-
tion. NPs formed by electrostatic interactions are less prone to aggregation due to
electrostatic repulsion from the surface charge. PEC NPs can complex with charged
molecules, such as anionic nucleic acids for gene delivery applications. Utilization of
charged polymers also permit facile modification/conjugation of nanoparticle surface
with other functional moieties. Furthermore, formation of polyelectrolyte complex
nanoparticles does not require additional crosslinking reagents. PEC NPs are also
ideal for binding/complexing charged molecules, such as negatively charged nucleic
acids [4, 5].
5Table 1.2: Polymers commonly used for PEC nanoparticle synthesis.
Fig. 1.3: Schematic representation of polyelectrolyte complex formation.
1.1.2 Heparin:Poly-L-Lysine Nanoparticles
Anionic heparin (Hep) and cationic poly-L-lysine (PLL) have been used to form
self-assembled PEC nanoparticles. Anionic heparin (Hep) and cationic poly-L-lysine
(PLL) have been used to form self-assembled PEC nanoparticles. Heparin (Figure
1.4A) is a naturally occurring glycosaminoglycan produced by mast cells. Heparin
is widely used as an anticoagulant to treat thrombosis, heart attack, and pulmonary
embolism. As a biomaterial, heparin is advantageous due to its affinity binding with
6a wide range of growth factors [6]. In addition to growth factors, heparin also binds
to extracellular matrix (ECM) proteins, plasma proteins, and enzymes [6].
PLL (Figure 1.4B) is a homopolymer polymerized by alpha amine of L-lysines.
PLL has been used to coat contrasting agent nanoparticles to increase transfection
efficiency for acoustical imaging and magnetic resonance imaging [7,8]. PLL has also
been employed to amplify signal for detecting amyloid , a potential biomarker for
Alzheimer’s Disease [9]. Additionally, PLL has been used to create variable viscoelas-
tic nanotopographies, via laser interference lithography and layer-by-layer techniques
to regulate stem cell behavior [10].
Fig. 1.4: A) Represented chemical structure of heparin. B) Chemical structure of
poly-L-lysine.
Heparin/PLL nanoparticles have been used to improve biocompatibility of stents
[11] and a cell delivery vehicle [12], as well as deliver laminin [13] and growth factors
[14,15]. Table 1.3 summarizes recent examples of heparin/PLL nanoparticles.
7Table 1.3: Previously reported uses and preparation methods of hep/PLL
nanoparticles [11–17].
81.2 Surface Modification of Nanoparticles
Nanoparticle surface modification allows for compensation of shortcomings of the
material used in fabrication, such as poor biocompatibility or propensity to aggre-
gate. Surface modification also allows for the addition of functionality, such as cov-
ering the surface with PEG for cellular evasion. Gold NPs have been modified using
self-assembled monolayers (SAMs) (Figure 1.5A). SAMs are formed by congregating
organic molecules that have been absorbed onto the surface of a substrate. For ex-
ample, the strong affinity between thiol and gold could be employed for the addition
of thiol containing molecules onto a gold nanoparticle surface. NP surface can also
be modified with an additional layer of polymers that have opposite charge to that of
the underneath substrate (Figure 1.5B). This method is commonly employed for the
addition of a more biocompatible material, such as heparin or hyualronic acid, which
reduces cytotoxicity of cationic polymers.
In addition to physical adsorption, NP surface can be modified chemically with
various methods, such as using carbodiimide coupling chemistry to conjugate car-
boxylic acid containing molecules onto a NP with surface primary amines. For exam-
ple, Bramberger et al. reduced spleen cell binding of particles by modifying nanopar-
ticles’ surface with PEG via reacting N-Hydroxysuccunimide (NHS) modified PEG to
NP surface amines [18]. The binding between biological components, such as biotin
and avidin can also be employed for NP surface modification. For example, Mat-
sumura et al. conjugated monoclonal antibodies, via biotin-avidin binding onto the
surface of a metal-latex nanocomposites. Consequently, the nanocomposite acted as
a detection probe for influenza virus [19].
9Fig. 1.5: A) Schematic representation of self assembled monolayer addition onto a
gold substrate. The green thiol affixes to the gold surface and the red functional
group is separated by an alkyl chain. B) Schematic representation of
layering-by-layer addition of oppositely charged polymers on a surface.
Adding functionality is of great importance for targeting, tracking, and cellular
evasion or uptake. Conjugating a handle on NP surface permits further attachment
of modified peptides, fluorescent tag, antibody, and polymers (e.g., PEG), as shown
in Figure 1.6. Attaching an antibody to the NP surface could improve binding of
NPs to specific receptors on cell surface. On the other hand, modifying a NP surface
with PEG, a technique termed PEGylation, effectively reduces non-specific cellular
uptake and increases plasma circulation time [18, 20–22]. For example, Viard, M.,
et al. modified phospholipid based nanostructure with PEG to improve circulation
time and efficacy of cancer treatment [23]. Another approach to prevent non-specific
clearance is through addition of CD-47 protein onto the NP surface [24]. CD-47
protein can provide cellular evasion by signaling to the cell that the NP is not a
foreign entity [24].
10
Fig. 1.6: Schematic representation of nanoparticle surface modification.
1.2.1 Tetrazine-Norbornene Click Chemistry
Click reactions offer powerful options for functionalization of polymers and nano-
particles. Proceeding without addition of catalysts or altering pH, click reactions can
functionalize materials without worrying about side reactions and altering the electro-
static interaction in the nanoparticle. Tetrazine(Tz):norbornene(NB) reaction, shown
in Figure 1.7 is a bioorthogonal click reaction capable of spontaneous reaction with
each other without reacting with other molecules in the body. Jivan et al. employed
Tz:NB click reaction to tethered glucose oxidase onto a microparticle without losing
enzyme bioactivity [25]. Han et al. used Tz:NB click chemistry to labeled epidermal
growth factors with quantum dots in order to label human skin cancer cell, which
over expresses epidermal growth factor receptors [26]. Han et al. utilized Tz:NB click
reaction to label quantum dots with antibodies for in vivo single cell labeling [27].
Fig. 1.7: Schematic representation of tetrazine-norbornene reaction.
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1.3 Nanoparticle-Induced Macrophage Polarization
As part of the immune system, macrophages play an important role in eliminating
foreign materials, cellular debris, bacteria, pathogens, and cancer cells through phago-
cytosis. Macrophages also elicit inflammatory response through secretion of cytokines.
Macrophages are generally categorized into M1 and M2 phenotypes. M1 macrophage
are activated to defend against viral and bacterial infections. M1 macrophages per-
form phagocytosis of foreign entities and are responsible for releasing proteases and
pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6, and tumor necrosis
factor alpha (TNF-α). M1 macrophages can be activated through the administra-
tion of lipopolysaccharide (LPS) or interferon gamma (INF-γ). M2 macrophages are
anti-inflammatory. They are responsible for removing cellular debris while eliciting
an anti-inflammatory environment with the production of cytokines, such as IL-10,
and TNF-β. M2 macrophages can be activated through the administration of IL-4
and IL-13.
Due to the macrophages ability to influence the local environment, influencing
macrophage activation state could offer a control of the inflammation of the local en-
vironment. This potential influence over inflammation could prove beneficial for treat-
ment of diseases affecting inflammation, such as arthritis. Influencing macrophage cy-
tokine production could also influence response from other immune cells which could
be beneficial for treating cancer. In general, modulation of macrophage phenotype
could prove beneficial for disease treatment. For example, Huang et al. demon-
strated ethylenediamine conjugated dextran and polyethylenimine (PEI) repolarized
tumor-associated macrophages (TAMs) from M2 to M1 phenotypes for cancer im-
munotherapy [28]. TAMs are immune cells that have been influenced by the tumor
environment to exhibit M2 like tendencies and have been shown to increase metasta-
sis, proliferation, and angiogenesis of various tumors. The repolarized macrophages
from the PEI or ethylenediamine conjugated dextran treatment secreted more IL-12,
which stimulates natural killer cells and natural killer T cell. Furthermore, PEI and
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ethylenediamine modified dextran elicited an immune response through the TAMs
and successfully reduced tumor size. In another example, Kim et al. treated rheuma-
toid arthritis (RA) by modulating M1/M2 population with nanoparticles decorated
with manganese ferrite and ceria [29]. RA is an autoimmune disease with increased
inflammation of the synovial fluid, eventually leading to a breakdown of cartilage
and bone. It was found that hypoxia and reactive oxygen species (ROS) play a
large role in shifting macrophage polarization from M2 to M1 phenotype, leading to
a pro-inflammatory environment in RA. Furthermore, manganese ferrite and ceria
nanoparticles scavenge ROS and produce oxygen, leading to repolarization of M1 to
M2 macrophage and this repolarization reduced inflammation and promoted recovery
of the arthritic site.
To influence macrophage phenotypes, NPs can be employed to increase uptake of
a material (drug, nucleic acid, polymer, etc.) while providing targeting capabilities,
thereby improving treatment efficacy while reducing off target adverse effects.
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CHAPTER 2. OBJECTIVES
2.1 Overview
The overall goal of this thesis was to develop a nanoparticle system whose surface
properties can be modularly controlled. Ideally, these modular NPs can be modi-
fied to exhibit a wide range of surface properties for targeting specific areas of the
body and to elicit a change in cellular behaviors. Here, a modular NP scaffold was
fabricated to afford facile tagging of biomacromolecules (e.g., glycosaminoglycans or
GAGs, peptides, antibodies, fluorophores, etc.) for selective cell targeting. In partic-
ular, ultrasonication was employed for fabricating both the core NP scaffold and the
surface coating. Compared with vortexing or mechanical agitation, ultrasonication
provides stringent controls in synthesis conditions, which should produce NPs with
more reproducible sizes or narrower size distribution. In addition to layering NPs
with different GAGs, this thesis work also explored bioorthogonal click chemistry to
modify NP surface. Specifically, modular reactivity of tetrazine-modified NP surface
with norbornene-conjugated molecules was beneficial for altering cell targeting capa-
bility. Finally, the utilities of the fabricated modular NPs were demonstrated using
selective targeting of macrophages in vitro.
2.2 Objective 1: Development of Modular Nanoparticle System
The first objective of this thesis was to develop heparin/PLL NPs with modular
compositions and surface functionality. Specific tasks to accomplish this goal were:
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• To establish a two-step ultrasonication protocol for forming core-shell hep-
arin/PLL nanoparticles.
• To construct NPs with various surface coating of GAGs (e.g., heparin, dextran
sulfate).
• To demonstrate biorthogonal NP surface modification via norbornene-tetrazine
click chemistry.
2.3 Objective 2: Investigation of the Effect of Nanoparticles on Cellular
Uptake and the Polarization of Monocyte
The second objective of this thesis was to demonstrate the modular NPs can be
used to control cellular uptake and inflammatory cytokine production. Specific tasks
to accomplish this goal were:
• To test cytocompatibliity of the modular NPs.
• To examine the effect of NP modification on cellular uptake/recognition.
• To determine the effect of dextran sulfate coated NPs on IL-10 production from
J774A.1 cells.
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CHAPTER 3. MATERIALS AND METHODS
3.1 Materials
Poly-L-lysine hydrobromide (PLL, 120 kDa) was purchased from Polysciences Inc.
Heparin sodium (Hep, 16.3 kDa) was purchased from Celsus Laboratories. Eight-arm
PEG-OH (20 kDa) was purchased from JenKem Technology, USA. tetrazine-PEG5-
NHS ester, dithiolthereitol (DTT), deuterium oxide, sodium chloride, 1,9-dimethyl-
methylene blue zinc chloride double salt, N,N-dicyclohexylcarbodiimide (DCC), 4-
(dimethylamino)pyridine (DMAP), Norbornene-2-carboxylic acid, and diethyl ether
were purchased from Sigma-Aldrich. Acetic Acid was purchased from VWR Chem-
icals. Tetrazine amine, methyltetrazine amine, methyltetrazine-PEG4-amine were
purchased from Click Chemistry Tools. Dextran sulfate sodium salt (DS, 40 kDa) was
purchased from Alfa Aesar. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
and N, N-Diisopropylethylamine were purchased from TCI. N-Hydroxysuccunimide
(NHS), phenol, and N,N,Dimethylformamide (DMF) were purchased from Acros Or-
ganics. Lipopolysaccharide (LPS) was purchased from Cell Signaling Technology.
Paraformaldehyde was purchased from Macron Chemical. Dulbeccos modified ea-
gle medium (DMEM), fetal bovine serum (FBS), Dulbeccos Phosphate Buffered
Saline (DPBS), and 100X antibioticantimycotic (anti-2) were purchased from Hy-
clone. Saponin was purchased from Chem-impex International Inc. 4”,6-Diamidino-
2-phenylindole, dihydrochloride (DAPI) was purchased from Anaspec Inc. Fmoc-
protected amino acids, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyri-
dinium 3-oxid hexafluorophosphate, hexafluorophosphate azabenzotriazole tetram-
ethyl uronium (HATU), N,N,N,N -tetramethyl-O-(1H -benzotriazol-1-yl)uronium hex-
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afluorphosphate (HBTU),and hydroxybenzotriazole (HOBt) were purchased from ei-
ther Anaspec or ChemPep. Frifluoroacetic acid was attained from EMD. Sulfo-Cy5-
tetrazine was purchased from Santa Cruz Biotechnology.
3.2 Material Synthesis
3.2.1 Methyltetrazine or Tetrazine Modified Heparin
Heparin modifications employed standard carbodiimide crosslinker chemistry. Hep-
arin sodium salt was dissolved at room temperature in ddH2O with stirring. 5-fold
excess of EDC and NHS were then added to heparin solution and stirred at room
temperature for 30 minutes. In a separate container, 5 fold excess of methyltetrazine-
amine, tetrazine-amine, or methyltetrazine-PEG4-amine was dissolved in ddH2O and
kept from light. Once the 30minutes were complete, the solutions were combined
and stirred in the dark, over night. To purify the modified heparin, dialysis was per-
formed on the resulting solution (3500 MWCO) at room temperature for two days in
ddH2O and then lyophilized. Substitution was determined against a standard curve
of mTz-amine, Tz-amine, or mTz-PEG4-amine via Synergy HT microplate reader at
absorbance 523nm.
3.2.2 5(6) Carboxyfluorescene Modified Poly-L-Lysine
Modification of poly-L-lysine utilized carbodiimide crosslinker chemistry. 2 Fold
excess (compared to PLL) of 5(6) Caboxyfluorescene was dissolved at room temper-
ature in ddH2O with stirring and kept from light. 5-fold excess (compared to PLL)
of EDC and NHS was then added to 5(6)caboxyfluorescene solution and stirred at
room temperature for 30 minutes, while kept from light. In a separate container,
poly-L-lysine hydrobromide was dissolved in ddH2O and kept from light. Once the
30 minutes were complete, the solutions were combined, pH was adjusted to 6.8, and
stirred in the dark for 5 hours. To purify the modified PLL, dialysis was performed
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on the resulting solution (6-8kDa MWCO) at room temperature for two days ddH2O
and then lyophilized.
3.2.3 Photoinitiator LAP
Photoinitiator Lithium Phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) was syn-
thesized according to previously reported method [30].
3.2.4 Norbornene Modified GGGRGDS Peptide
GGGRGDS synthesis was performed via standard Fmoc coupling chemistry in
an automated, microwave-assisted peptide synthesizer (Liberty 1, CEM). The crude
products were cleaved from resin in a solution consisting of 2.5% ddH2O, 2.5% Tri-
sisopropylsilane, 95% trifluoroacetic acid, and 5% (w/v) phenol for 3 hours at room
temperature. The crude peptides were precipitated in cold ethyl ether and dried in
a desiccator. The dried peptides were purified using HPLC (Flexar system, Perkin
Elmer) and confirmed by mass spectrometry (QTOF, Agilent Technologies).
NB-GGGRGDS was synthesized via 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, Hexafluorophosphate Azaben-
zotriazole Tetramethyl Uronium (HATU) coupling reaction. 5-norbornene-2-carbox-
ylic acid (5 fold molar excess to peptide, 5X), HATU (5X), and 3 mL DMF were added
to a flask and stirred, via magnetic stir bar. N, N-Diisopropylethylamine (DIEA,
5.1X) was added to the solution and stirred for 3 minutes. The resulting activated
norbornene acid was added to a flask containing purified GGGRGDS in DMF and al-
lowed to react for 3 hours at room temperature, under stirring. The NB-GGGRGDS
product was precipitated in cold diethyl ether and dried in a desiccator.
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3.2.5 PEG Macromer
Methyl-PEG-NB, two arm PEG-diNB, and eight arm PEG-norbornene were syn-
thesized according to a previously reported method with minor modifications [31]. For
example, eight-arm PEG-norbornene (PEG8NB, 20 kDa) was synthesized as follows.
5-norbornene-2- carboxylic acid (5-fold molar excess to eight arm PEG-OH(PEG8OH)
hydroxyl groups(5X)) was reacted with DCC (2.5X) for 1 hour in anhydrous DCM,
resulting in norbornene anhydride. In a separate two-necked round bottom flask
PEG8OH, DMAP (0.5X), and pyradine (0.5X) were mixed with DCM under nitro-
gen. Upon completion of the hour, the norbornene anhydride was filtered to remove
by-products and added dropwise via addition funnel to the separate two-necked round
bottom flask containing PEG8OH while under nitrogen. The flask was removed from
light and the reaction was allowed to proceed overnight. The process was repeated to
improve norbornene functionalization of the PEG. The PEG8NB product was precip-
itated in cold diethyl ether and dried in a desiccator. The dried product was dissolved
in ddH2O and dialyzed for 3 days at room temperature (6-8 kDa MWCO), followed
by lyophilization. 1H NMR (Bruker Advance 500) was used to determine the degree
of PEG functionalization.
3.2.6 Linear Cy5-PEG-NB
Linear Cy5-PEG-NB was synthesized by mixing PEG-diNB (6kDa) with Cy5-
Tz for 1 hour. A NB/Tz ratio of 20 was used to ensure conjugation of Cy5-Tz to
PEG-diNB.
3.3 One-Step Nanoparticle Preparation
Specific volume of PLL dissolved in filtered (0.22mum PVDF) double distilled
water (fddH2O) was added to a test tube, followed by the addition of fddH2O, and
an aliquot of heparin dissolved in fddH2O. Total volume of 2mL was used for initial
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testing. The solution was sonicated using a Bronson Digital Sonifier at 19.9500.100
kHz, with 10% amplitude, for an initial duration of 5 minutes with the test tube in
ice water. For pulse sonication one step preparation, after the initial 5 minutes, a 10
min cool down period, followed by 2.5 min sonication, followed by 2 min cool down,
and 2.5min sonication.
The resulting solution was analyzed by dynamic light scanning via Malvern Zeta-
sizer Nano ZS90. The zeta potential was measured using Zetasizer Nano Series dis-
posable folded capillary cells. Nanoparticle size was measured utilizing UV-disposable
cuvettes.
3.4 Two-Step Nanoparticle Preparation
Separately, PLL, dextran sulfate, and heparin were dissolved in filtered (0.22mum
PVDF) double distilled water (fddH2O). Specific volume of PLL solution was added
to a test tube, followed by the addition of fddH2O, and an aliquot of heparin solution.
The ratio of Hep/PLL was 0.7 and the total volume of 2mL was used. 0.25mg/mL
PLL and 0.175mg/mL heparin were used for Hep/PLL ratio of 0.7. The solution was
sonicated using a Bronson Digital Sonifier at 19.9500.100 kHz, with 10% amplitude,
for an initial duration of 5 minutes. After around 8min of cooling down the solution,
additional material (Heparin, Heparin-Tz, heparin-mTz, Dextrin Sulfate) was added
to bring the ratio of Hep+additional material/PLL to 1.3. After the 10min cool
down, the solution was sonicated for 2.5min, followed by 2min cool down, and 2.5min
sonication.
The resulting solution was analyzed by dynamic light scanning via Zetasizer Nano.
The zeta potential was measured using Zetasizer Nano Series disposable folded cap-
illary cells. The size was measured utilizing UV-disposable cuvettes.
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3.5 Nanoparticle Stability
Nanoparticles were measured via Zetasizer Nano with UV-disposable cuvettes over
the course of a month.
Dimethyl methylene blue assay was performed as follows. DMMB solution was
prepped by first adding 16mg 1,9-deimethyl-methylene blue zinc chloride into 1L of
double distilled water containing 3.04g glycine, 1.6g sodium chloride, and 95mL of
0.1M acetic acid. The solution was then stirred and kept from light. A heparin
standard curve was prepared with concentrations from 40mug/mL to 5ug/mL with
a blank. 20muL of standards and samples were added to a 96 well plate. 180muL
DMMB solution was added to each well and the plate was measured by a Synergy
HT microplate reader via absorbance at 530nm.
3.6 Monitoring Heparin-mTz:Methyl-PEG-NB Reaction by 1H NMR
Methyl-PEG-NB and mTz-heparin were dissolved separately in deuterium oxide.
The solutions were mixed together, added to an NMR tube, and measured via 1H
NMR (Bruker Advance 500). A 3:2 ratio of mTz:NB was used.
3.7 Cy5 NPs and NP Hydrogel Hybrid
Tz-heparin coated nanoparticles and linear Cy5-PEG-NB at a Tz:NB ratio of 1:1
were mixed for 24hours. Once mixing was complete, the solution was centrifuged
for 25 minutes at 14,000 RPM. The supernatant was removed and the pellet was
resuspended in ddH2O. This step was repeated two more time to remove excess Cy5-
PEG-NB. Solution was placed in bath sonicator for 5min.
PEG8NB (3wt%), Cy5-PEG-NPs (7.3wt%), and PBS were kept from light and
mixed for 24hrs. Desired amounts of DTT, with a thiol/ene ratio of 0.9 and LAP
(1mM) photoinitiator were mixed in and the resulting solution was injected between
two slides, separated with 1mm Teflon spacers. The solutions were then subjected
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to 365nm light (5 mW/cm2) for 2 minutes. Resulting gels were transferred to PBS,
kept from light, and allowed to swell prior to confocal imaging.
3.8 Cell Viability
J774A.1 cells were seeded (5,000 cells per well) into a 96 well plate. Cells were
treated with varying concentrations of PLL, Hep, DS, and 1.3 Hep/PLL NPs. Cells
were confluent at the time of measurement. For the NP study, equal concentration
of PLL was in solution as within the NP. Cells were incubated for 3 hrs followed
by administration of sterile 0.4mg/mL thiazolyl blue tetrazolium bromide solution
in serum free DMEM high glucose media and removed from light. Solution was
incubated at 37oC for 2 hours. Upon completion of incubation, 120muL of DMSO
was added. The solution was mixed and 100muL was transferred to a 96 well plate
for reading on microplate reader with a 570nm wavelength.
3.9 Nanoparticle Uptake by 3T3 and J774A.1 Cells
First, 75,000 J774A.1 cells were seeded on 35mm tissue culture plates. Non-
activated cells are allowed to culture in DMEM high glucose culture media with 10%
fetal bovine serum and 1% antibioticantimycotic (anti-2) for 3 days before nanopar-
ticle administration. Activated cells were allowed to culture for 2 days followed by
administration of 1mug/mL lipopolysaccharide (LPS) and allowed to culture for 1
day before nanoparticle administration. Two step nanoparticles were prepared with
dextran sulfate, heparin, or Tz-heparin coating. NPs were prepared with 0.25mg/mL
PLL-5,6-carboxyfluorescene. Tz-Heparin coated nanoparticles were mixed with one
arm linear PEGNB (5.5 NB:Tz) for 24 hours. Heparin and dextran sulfate coated NPs
were mixed with an equal volume of fddH2O for 24 hours. A mixture of 10% sterile NP
solution and 90% media was administered to the cells for 4 hours. Upon completion
of the 4 hours, media was removed and cells were fixed with 4% paraformaldehyde,
treated with saponin, and stained with DAPI. Images were taken with a confocal mi-
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croscope (Olympus Fluoview FV100 laser scanning microscope), with DAPI used to
focus the image. Images were quantified by ImageJ by measuring the mean intensity
of the FITC image and counting cells of the DAPI image.
100,000 3T3 cells were seeded on 35mm tissue culture plates. Cells were cultured
for 3 days in DMEM high glucose culture media with 10% fetal bovine serum (FBS)
and 1% anti-2 for 3 days before nanoparticle administration. Two step nanoparti-
cles were prepared with dextran sulfate, heparin, or Tz-heparin coating. NPs were
prepared with 0.25mg/mL PLL-5,6-carboxyfluorescene. Tz-heparin coated nanopar-
ticles were mixed with one arm linear PEGNB (5.5 NB:Tz) for 24 hours. Heparin and
dextran sulfate coated NPs were mixed with an equal volume of fddH2O for 24 hours.
A mixture of 10% sterile NP solution and 90% media was administered to the cells
for 4 hours. Upon completion of the 4 hours, media was removed and cells were fixed
with 4% paraformaldehyde, treated with saponin, and stained with DAPI. Images
were taken with a confocal microscope, with DAPI used to focus the image. Images
were quantified by ImageJ by measuring the mean intensity of the FITC image and
counting cells of the DAPI image.
3.10 RGD-Bound Nanoparticle Recognition by 3T3 Fibroblast Cells
100,000 3T3 cells were seeded on 35mm tissue culture plates. Cells were cultured
for 3 days in DMEM high glucose culture media with 10% fetal bovine serum (FBS)
and 1% anti-2 for 3 days before nanoparticle administration. Two step nanoparticles
were prepared with dextran sulfate, heparin, or Tz-heparin coating. NPs were pre-
pared with 0.25mg/mL PLL-5,6-carboxyfluorescene. Tz-heparin coated nanoparticles
were mixed with NB-GGGRGDS peptide (10:1 peptide:Tz) for 24 hours. Heparin
coated NPs were mixed with an equal volume of fddH2O for 24 hours. A mixture of
10% sterile NP solution and 90% media was administered to the cells for 4r hours.
Upon completion of the 4 hours, media was removed and cells were fixed with 4%
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paraformaldehyde, treated with saponin, and stained with DAPI. Images were taken
with a confocal microscope, with DAPI used to focus the image.
3.11 Effect of NPs on LPS Treated Cells
100,000 J774A.1 cells were seeded on 35mm tissue culture plates. Cells were
cultured with DMEM high glucose media (10% FBS, 1% anti-2). After 24 hours, LPS
(1mug/mL) in media (1.2mL) was administered to the plate. After an additional 24
hours, a 1.2mL solution of 10% NP/Soluble DS/fddH2O in media was administered.
After an additional 24 hours, the media was removed and frozen (-80oC freezer)
for later measurement with an enzyme linked immunosorbant assay (ELISA). Cells
were fixed, treated with saponin, stained with DAPI, and imaged with a confocal
microscope. Images were used for cell counting and estimated the plate density.
3.12 Effect of LPS on NP Treated Cells
100,000 cells (J774A.1) were seeded on 35mm tissue culture plates with DMEM
high glucose media (10% FBS, 1% anti-2). After 44 hours, a 1.2mL solution of 10%
NP/Soluble DS/fddH2O in media was administered. After 4 hours, LPS (1mug/mL)
in media was administered. After an additional 24 hours, the media was removed and
frozen (-80oC freezer) for later measurement with an enzyme linked immunosorbant
assay (ELISA). Cells were fixed, treated with saponin, stained with DAPI, and imaged
with a confocal microscope. Images were used for cell counting and estimated the
plate density.
3.13 Statistical Analysis
Quantitative results are reported as mean SEM. Two-tailed t-tests and two-way
analysis of variance ANOVA with a Bonferroni post test were utilized in determining
of significance. Significance was considered with a p values ¡0.05, ¡0.01, and ¡0.001,
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corresponding to single, double, and triple asterisks respectively. Experiments were
performed in an independent fashion, at least in duplicate.
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CHAPTER 4. RESULTS AND DISCUSSION
4.1 One-Step Nanoparticle Formation
Polyelectrolyte complex nanoparticles were fabricated with poly-L-lysine (PLL),
a polycation and heparin, a polyanion under ultrasonication conditions, as shown in
Figure 4.1A. Nanoparticles were initially formed with 5 minute sonication. In Figure
4.1B, varying the heparin to PLL weight ratio allowed for control of the surface charge.
The surface charge mirrors the more predominant surface polymer species, therefore
the surface charge can be controlled via the heparin to PLL weight ratio. For example,
the 0.7 [hep]/[PLL] NP had a positive zeta potential, so PLL would be the more
predominant polymer on the surface of the NP. While the charge is altered, varying
the heparin/PLL weight ratio does not greatly alter the size, as shown in Figure
4.1.C and Table 4.1. Compared to reported NP size data (as shown in Table A.1),
the size of these nanoparticles were smaller. This could possibly due to the molecular
weight, preparation method, and concentrations of the heparin and PLL employed
during fabrication. In Table B.1, the increase in heparin and PLL concentrations
increased NP size. In Table A.1, the papers reporting the same molecular weights and
ultrasonic conditions had a range of sizes, suggesting that the particular sonication
protocol can alter NP size. Muller et al. demonstrated the size of PEC NPs composed
of polyethyleneimine (PEI) and poly(acrylic acid) could be altered by adjusting the
molecular weight of PEI [32]. Heparin/PLL nanoparticles may respond in a similar
way.
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Fig. 4.1: A) Schematic representing basic nanoparticle synthesis. B) Zeta potential
of NPs with varying [Hep]/[PLL] ratios at a constant [PLL] of 0.25 mg/mL. C)
Representative size distribution data.
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Table 4.1: Size and PDI for [Hep]/[PLL] ratios at a constant [PLL] of 0.25 mg/mL.
4.2 Pulse Preparation Sonication and Two-Step Nanoparticle Formation
Polydispersity index (PDI) is a measure of particle size uniformity. PDI can
influence the therapeutic performance of the NPs since the NP size can influence
route of endocytosis, loading efficiency, and release rate [33,34]. To further elaborate,
should the NP size distribution be large, there will be a wider range of release rates
some NPs could release drug prior to reaching the intended site, thereby increasing off-
targeting problems. Should the method of endocytosis affect drug delivery strategy,
then a larger size distribution could have NPs not taken up by the intended route into
the cell, thereby reducing the effectiveness if the secondary route is ineffective. With
a goal of creating a nanoparticle system that can be repurposed for several different
strategies, a lower PDI would be desired. As such, the sonication technique employed
for NP fabrication was adjusted with a goal of lowering PDI. Figure 4.2.A shows
three methods of sonication. Here, pulse sonication was used to represent a procedure
composed of alternating sonication and cool down periods. As shown in Figure 4.2B
and Table 4.2, pulse sonication (i.e., condition B) yielded NPs with significantly lower
size and PDI. The additional sonication beyond the initial five minute duration likely
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caused the loosely bound polymers to detach from the majority of the NPs, thereby
leading to a more compact NP (Figure 4.2C).
Fig. 4.2: A) Preparation timing for comparison of 1 step (A and B) and 2 step (C)
method with constant overall concentrations of [Hep] 2mg/mL and [PLL]
1.538mg/mL. B) PDI results for the different preparations noted in A. C) Schematic
representation of shedding loosely bound polymer. D) Schematic revealing the 2
step approach (preparation C).
Represented in Figure 4.2D, a two-step nanoparticle preparation method was
developed. The two-step NP preparation method consisted of formation of a core
nanoparticle with positive surface potential, followed by layering a polyanion (i.e.
dextran sulfate, Tz-modified heparin, hyaluronic acid etc.). The timeline of material
addition and sonication parameters employed for the two-step NP preparation method
are shown as line C of Figure 4.2A. The core NP was comprised of a [Hep]/[PLL] ratio
of 0.7 had a positive surface potential. The [Hep]/[PLL] ratio of 0.7 was chosen to
provide adequate positive surface charges (Figure 4.1B). Upon addition of heparin,
the layered NP [Hep]/[PLL] was 1.3, with a negative zeta potential (Table 4.2, prepa-
ration C). The [Hep]/[PLL] weight ratio of 1.3 was chosen due to the surface potential
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(Figure 4.1B) had stabilized. In Table 4.2, comparing the NP size of preparations B
and C, there is a significant increase in diameter. Considering the change in surface
charge and increase diameter, the additional material was likely to be added to the
surface of the NP and not reorganizing the NP completely. In Table B.2, the layering
method was employed to add dextran sulfate and modified heparin onto the NP sur-
face. Size, zeta, and PDI were similar between surface heparin and surface dextran
sulfate NPs.
Table 4.2: Table of size and zeta potential for preparation timeline in Figure 4.2.
4.3 Nanoparticle Stability
Shelf life, as determined by the stability of a product plays an important role
for a biomedical material, since a short shelf life biomedical material will be less
likely to be used. The nanoparticle stability was determined via DLS and dimethyl
methylene blue (DMMB) assay over the course of a month. PDI, a measure of particle
size uniformity has a scale where 0 is completely uniform and 1 in completely non-
uniform. Measurements above 0.700 is considered to be too disperse for accurate
DLS measurements. A large increase in PDI over sequential measurements is an
indication of instability of PEC NPs. Shown in Figure 4.3A and Table 4.3A, the core
nanoparticle with surface PLL (0.7 [hep]/[PLL]) had consistent size and PDI for the
month of testing. Similar to the core nanoparticle, the NPs formed from two-step
pulse sonication with surface heparin (1.3 [hep]/[PLL]) had consistent size and PDI
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for at least a month, as seen in Figure 4.3B and Table 4.3B. The consistent size and
PDI suggests the NPs are stable for at least a month.
Table 4.3: A) Size and PDI over time for 0.7 weight ratio ([PLL] 0.25 mg/mL)
nanoparticles. B) Size and PDI over time for 1.3 weight ratio ([PLL] 0.25 mg/mL)
nanoparticles.
In addition to size and PDI measurements, DMMB assay, a method for quantifying
glycosaminoglycan content (e.g., heparin), was employed to evaluate the stability of
the nanoparticles. Initial measurements of the core NP (0.7 [hep]/[PLL]) surprisingly
revealed the heparin in the core was not measurable, therefore DMMB did not have
access to the heparin. As such, DMMB seemed to offer another method for measuring
the stability of the NPs, since a degradation of the NP would result in liberation of
heparin into the solution. Within a month, there was no measurable heparin in the
solution incubated with the core NP, suggesting the NP did not disintegrate and were
stable for that time period. Heparin contents in the NPs formed from two-step pulse
sonication were also measured via DMMB, which revealed that a portion of the total
heparin was measurable. Since the PLL of the core may have masked the core heparin
from detection, the DMMB measurements in the samples with NPs formed from two-
step pulse sonication were indicative of heparin released to the buffer or still bound
to NP surface. An increase in heparin content would signify NP disintegration. As
shown in Figure 4.2.C, the heparin content in solution did not increase, suggesting
the NPs are stable for at least a month, in agreement with DLS data.
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Fig. 4.3: A) Histogram overlay of 1.3 weight ratio NP size data for days 0, 15, and
29. B) Histogram overlay of 0.7 weight ratio NP size data for days 0, 17, and 29. C)
Assessing stability of 1.3 weight ratio nanoparticles with [PLL] of 0.25 mg/mL using
DMMB assay. Note: 0.7 weight ratio nanoparticle DMMB study was performed,
but no heparin was recorded throughout the month long study.
4.4 Reaction Capabilities of Methyltetrazine Modified Heparin
Heparin was modified with tetrazine (Tz) and methyltetrazine (mTz) in order to
utilize Tz:NB click chemistry for modular NP surface modification. Tz or mTz modi-
fied heparin (Tz-heparin or mTz-heparin) were synthesized via standard carbodiimide
chemistry, as represented in Figure 4.4. Briefly 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-Hydroxysuccunimide (NHS) were mixed with heparin to
activate the carboxylic acids on heparin. The NHS-ester formed in the activated hep-
arin will react with tetrazine-amine or methyltetrazine-amine to form amide bonds
between heparin and Tz or mTz. Employing the two-step pulse sonication method,
the modified heparin could be layered onto the NP surface to act as a handle for
modular modification with NB-modified bioactive cues.
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Fig. 4.4: Schematic representation of the carbodiimide crosslinker reaction with
heparin and methyltetrazine amine.
The reaction kinetics of mTz-heparin and a linear methyl-PEG-NB was monitored
via 1H NMR. As shown in Figure 4.5A, reactions between mTz and NB moieties would
result in shifting of proton peaks corresponding to the hydrogen atoms of the mTz
aromatic ring (peaks A, A, B, B) and reduction NB associated protons (peaks C
and D). Figure 4.5B shows an overlay of 1H NMR spectra where gradual reduction
of norbornene proton signals and reduction of mTz proton signals were detected for
samples reacted from 0.2 to 24 hours. Figure 4.5C shows the kinetics of NB-mTz
reaction. Note that there was residual norbornene proton signals left after 24 hours
of reaction. This could be attributed to the amount of mTz and NB added were
both based on calculations, which potentially led to more NB than mTz in solution.
The inaccuracy in the actual concentration may be attributed to the heterogeneous
manner of heparin, leading to less mTz used in testing than calculated. Regardless,
the reaction proceeded spontaneously and was completed by about 24 hours. The
reaction kinetics of Tz-NB was also attempted using the same method; however, the
reaction was difficult to quantify owing to the rapid reaction rate between NB and
Tz [35].
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Fig. 4.5: A) Structure of methyltetrazine (mTz), Norbornene (NB), and the result
of the reaction with proton labeling corresponding to peaks in Figure 4B. B)
Overlay of 1H NMR chromatographs of Heparin-mTz and one arm PEGNB reaction
taken at specific time points. C) Graph representing NB consumption as the
reaction progresses. B/B’ peaks were set as a reference peak and A/A’ were used as
confirmation.
4.5 Reaction of Surface Tetrazine Nanoparticles with Norbornene
Modified Species
To demonstrate that the NP surface tetrazine can be used for bioconjugation, a pi-
lot study was performed for attaching norbornene-functionalized fluorescent molecules.
First, two step NPs were created with Tz-heparin or mTz-heparin, as shown in Ta-
ble B.2. The NP size and PDI were not greatly affected between NPs formed with
Tz-heparin or mTz-heparin coating and NPs formed with heparin coating. However,
a decrease in zeta potential was noted, probably due to a reduction of carboxylic
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acid due to the EDC/NHS reaction. For surface conjugation, a linear Cy5-PEG-NB
was synthesized by first modifying linear PEG-OH with norbornene. The resulting
PEG-NB was then reacted with Cy5-Tetrazine at a Tz:NB molar ratio of 1:20. The
linear Cy5-PEG-NB was employed to tag a fluorescent probe onto the NP via Tz:NB
reaction, as represented in Figure 4.6A. The Cy5-PEG-NB and Tz-Hep coated NPs
were simply mixed and incubated for 24 hours. Next, the NP solution was washed
three times, centrifuged and resuspended in fresh ddH2O in order to remove unre-
acted Cy5-PEG-NB. A droplet of this solution was imaged via confocal microscope
(Figure 4.6B). The dotty red Cy5 fluorescence in the images was indicative of success-
ful tagging of Cy5 to the surface of NPs. The Cy5-tagged NPs were also entrapped
into a hydrogel for visualization. The NP-loaded hydrogels were swelled to remove
unreacted soluble Cy5-PEG-NB. The NP-loaded hydrogels were imaged by confocal
microscope (Figure 4.6C). Aggregation was noted and the origin was determined to be
from the concentration step, since repeated studies without concentration step showed
no aggregation. In Figure 4.6B and C, signal corresponding to Cy5 was present in the
droplet and hydrogels. The confocal images of Figure 4.6 suggest the NB-PEG-Cy5
species was clicked onto the nanoparticles and demonstrated the Tz-heparin are on
the NP surface and are available to react with norbornene modified species.
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Fig. 4.6: A) Schematic representation of addition of PEG-Cy5 to the surface of the
nanoparticle via tetrazine (Tz) norbornene (NB) click chemistry. Cy5 fluorescence
confocal image of 2 step Cy5 NPs in the edge of a droplet (B) and in the center of a
hydrogel (C). Scale 200 µm.
4.6 Cytotoxicity of Components and Nanoparticles
Cytotoxicity of NPs and their constituent polymers were determined via MTT as-
says on J774A.1 monocytes. In Figure 4.7A, high concentration of heparin (20mg/mL)
caused slight reduction in cell viability. However, at the concentrations used for NP
preparation heparin did not exhibit cytotoxic effect. As shown in Figure 4.7B, dex-
tran sulfate was not toxic to the cells for all concentrations tested. On the contrary,
poly-L-lysine was determined to be highly cytotoxic (Figure 4.7C), including at the
concentration in NP fabrication (0.25mg/mL). Considering the cytotoxic effect of
PLL, it was critical to evaluate the cytotoxicity of nanoparticles. As shown in Figure
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4.7D, the NP cytotoxicity assay was performed with equal concentrations of PLL
for NP and soluble PLL groups. In spite of the use of a soluble PLL concentration
that would have cause cell death, NPs formed at this PLL concentration actually
promoted cell proliferation as more than 100% of MTT signals were obtained from
these samples when compared with the control group. It was possible that these NPs,
which were heparinized on the surface, sequestered more serum proteins and resulted
in increased uptake by the cells. Consequently, forming NPs with surface heparin
not only reduced the cytotoxicity of PLL, but also exerted an unexpected effect on
promoting cell proliferation.
Fig. 4.7: MTT assay determining cell viability of J774A.1 monocyte cells with 4hrs
of incubation with nanoparticle components. Components are: A) heparin, B)
dextran sulfate, and C) poly-L-lysine. D) MTT assay determining J774A.1 cell
viability with 24 and 48 hour incubation with 2 step heparin surface nanoparticles.
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4.7 Modulation of Nanoparticle Recognition/Uptake by J774A.1
Monocytes, Macrophages, and 3T3 Fibroblasts
Modulation of cellular uptake/recognition of NP is important for targeted de-
livery of therapeutics to cells. When delivered into the body, NPs can be cleared
by macrophages, which is problematic for therapeutic applications of nanoparticle.
Strategies to increase NP circulation time are therefore important as they can increase
the amount of drug getting to the desired location. Modulating uptake/recognition
could also increase interaction of a nanoparticle with a specific cell type for treatment.
As such, an investigation into the uptake modulation capabilities of the NPs formed
by two-step pulse sonication was undertaken. NPs formed by two-step pulse sonica-
tion were prepared with dextran sulfate, heparin, or Tz-heparin coating (Table B.2).
Tz-heparin NPs were used as they can be PEGylated (through reacting with linear
PEG-NB). The PEG polymer chains can ’shield’ the NP from macrophages, thereby
improving circulation time. The studies were performed on naive (non-LPS treated)
and LPS-activated J774A.1 cells. Monocytes (e.g., nave J774A.1) and macrophages
(e.g., LPS-activated J774A.1) are both immune cells that are likely to come in con-
tact with NPs. A non-immune cell type, NIH/3T3 fibroblast was used as a non-target
cell type. To visualize NP uptake by the cells, PLL was first fluorescently labeled
with 5(6)-carboxyfluorescene (5(6)-Fam) prior to incorporating into the NPs. In the
first study, the ability of the NPs to modulate cellular uptake/recognition by LPS-
activated macrophages was evaluated. Since macrophages are in tissue, this cell type
is likely to come in contact with NPs, potentially close to the site of treatment. As
such, the NPs were administered to LPS activated J774A.1 macrophages, which ex-
hibited an M1 phenotype [37-39]. In 5(6)-Fam column of Figure 4.8A, there is a clear
decrease in fluorescence between heparin-coated NP and PEGylated NP groups. The
cell nuclei were counter-stained with DAPI for cell counting, while differential inter-
ference contrast (DIC) images were obtained to show cell morphology. The spread cell
morphology of a large portion of the cell population confirmed the LPS activation of
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the J774A.1 monocytes. Figure 4.8B shows the results of image analysis where fluo-
rescent intensity was normalized to cell number. Clearly, PEGylation of NP decreased
cellular uptake, which is in agreement with previously reported literature [18,20–23].
Furthermore, comparing NPs coated with Tz-heparin and with heparin, there was no
significant difference in the amount of NP uptake by the cells. Therefore, it can be
concluded that the surface tetrazine was not responsible for the decrease in cellular
uptake for the PEGylated group.
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Fig. 4.8: A) Nanoparticle uptake by LPS activated J77A.1 cells after four hours of
treatment. NPs had surface of either dextran sulfate, heparin, or heparin-Tz
conjugated with linear PEG-NB. Nanoparticles were modified with 5(6) carboxy
fluorescene for imaging purposes. Scale 100µm. B) Intensity of 5(6)-fam per cell
were determined for images of LPS activated J774A.1 cells with corresponding
surfaces. (approximately 300 cells per image).
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In the second study, the ability of the NPs to modulate cellular uptake/recognition
by monocytes was evaluated. Since monocytes are in blood, NPs are almost certain
to come in contact with this cell type. In 5(6)-Fam column of Figure 4.9A, again
there is a clear decrease in fluorescence between heparin coated NP and PEGylated
NP groups. The morphology of the cells treated with PEGylated NPs were more
circular, suggesting that the cells remained as nave monocytes. However, there was
more spreading in the cells treated with either dextran sulfate or heparin coated
nanoparticles, suggesting that the cells could have been activated due to the uptake
of NPs. Figure 4.9B shows the results of image analysis where fluorescent intensity was
normalized to cell number. Again, PEGylation of the NPs decreased cellular uptake,
similar to that observed in the experiment with LPS-activated J774A.1 macrophages.
41
Fig. 4.9: A) Nanoparticle uptake by non-activated J77A.1 cells after four hours of
treatment. NPs had surface of either dextran sulfate, heparin, or heparin-Tz
conjugated with linear PEG-NB. Nanoparticles were modified with 5(6) carboxy
fluorescene for imaging purposes. Scale 100µm. B) Intensity of 5(6)-fam per cell
were determined for images of non-activated J774A.1 cells with corresponding
surfaces. (approximately 500 cells per image).
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In the third study, the ability of the NPs to modulate cellular uptake/recognition
by non-immune cells was evaluated. Off target binding to cells not intended for
treatment can be problematic for therapeutic applications. Therefore, a study was
performed to evaluate whether NP surface modification altered uptake/recognition
by non-immune cells. In 5(6)-Fam column of Figure 4.10A, there is a clear decrease in
fluorescence between heparin coated NP and PEGylated NP groups as well as between
heparin coated NP and dextran sulfate coated NPs. Figure 4.10B shows the results
of image analysis where fluorescent intensity was normalized to cell number. Clearly,
PEGylation of NP decreased cellular uptake, which agrees with previous data. Dex-
tran sulfate coated NPs also clearly decreased cellular uptake. In the previously shown
data, dextran sulfate coating did not change uptake by monocytes/macrophages. As
a component of the ECM, heparin likely interacts with fibroblast cells. As product
of gram negative bacteria, dextran sulfate probably does not regularly interact with
fibroblast cells. Therefore, a reduction of recognition from NP surface heparin to
surface dextran sulfate is not surprising.
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Fig. 4.10: A) Nanoparticle recognition/uptake by 3T3 cells after four hours of
treatment. NPs were coated with either dextran sulfate, heparin, or heparin-Tz
conjugated with linear PEG-NB. Nanoparticles were modified with 5(6) carboxy
fluorescene for imaging purposes. Scale 100µm. B) Intensity of 5(6)-fam per cell
were determined for images of 3T3 cells with corresponding surfaces.
(approximately 500 cells per image).
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The ability to selectively target a specific cell type reduces off targeting effects,
making for a more effective therapeutic carrier. Therefore, NP uptake by different
cells were compared. As shown in Figure 4.11, J774A.1 cells clearly uptake more NPs
than 3T3 fibroblasts, regardless of NP formulations. This revelation was expected
due to the nature of the J774A.1 monocytes/macrophages, tasked with clearance of
foreign entities. Figure 4.11 also shows that dextran sulfate coating can be employed
to aid in selective cell targeting. Dextran sulfate may be selective due to macrophage
scavenger receptor A recognizes and mediates endocytosis of dextran sulfate [36,37].
Macrophages are responsible for elimination of foreign mater and production of pro
or anti-inflammatory cytokines. As such, a macrophage targeting platform would
prove to be beneficial for disease treatment. Macrophages in inflammatory diseases
are activated to the M1 phenotype, producing pro-inflammatory cytokines and re-
ducing the ability for the area to heal. Reduction of the M1 population or repolarize
M1 macrophage to the anti-inflammatory M2 macrophage could aid in recovery of
arthritic tissue. As such, the ability to selectively target macrophage for inflammatory
disease treatment is very beneficial. The selective cell targeting by dextran sulfate
also suggests the NPs formed from two-step pulse sonication can employ layering a
variety of polyanions for modifying how the NPs interact with cells.
45
Fig. 4.11: A) Comparison of cellular uptake with similar cell density (approximately
500 cells per image).
4.8 RGD-Bound Nanoparticle Recognition by 3T3 Fibroblast Cells
To further demonstrate the ability of the NPs formed from two-step pulse sonica-
tion to modulate cellular recognition, an integrin binding peptide was affixed to the
surface of the NPs. As a trans-membrane receptor, integrin facilitates cell adhesion
to the ECM. Attaching RGD to a NP surface has been employed as a method for in-
creasing colocalization of NPs to a cells surface for disease treatment, such as a breast
cancer with an over expression of integrins [38]. A model GGGRGDS peptide, which
contains the integrin binding sequence RGD, was modified with norbornene via HATU
coupling reaction. Briefly, 5-norbornene-2-carboxylic acid and HATU were mixed to
activate the carboxylic acid group. Purified GGGRGDS was then added to the acti-
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vated norbornene solution. The peptide N-terminal primary amine reacted with the
activated carboxylic acid to yield a norbornene-modified RGDS peptide. The NB-
GGGRGDS peptide was affixed to heparin-Tz coated NPs via Tz:NB click reaction.
NPs with and without the RGD peptide were administered to 3T3 fibroblasts. As
shown in Figure 4.12, the control NPs (no RGDS sequence) and RGDS modified NPs
were equally distributed throughout the cells. RGD peptide sequence has been shown
to bind to several different integrins [39]. As such, this result was not expected, going
against previous research data demonstrating the use of NP surface RGD to improve
cellular localization [38,40]. The deviation from previous data may be due to heparin
exhibiting non-specific binding to fibroblast cells, masking the effect of the NP mod-
ification. As such, future testing could use a bio-inert polyanion, such as alginate to
modify with RGD peptide sequence. Without non-specific binding to the cells, RGD
modification of alginate coated NPs should be able to modulate cellular localization.
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Fig. 4.12: Images of NP recognition by fibroblast (3T3) cells. NPs were coated with
either heparin or heparin-Tz conjugated with NB-GGGRGDS. Cells were treated
with nanoparticles for four hours. Nanoparticles were modified with 5(6) carboxy
fluorescene for imaging purposes. 100,000 cells were seeded and cultured three days
prior to NP treatment. Scale 100µm.
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4.9 Tuning J774A.1 Macrophage Activation
To demonstrate the ability of the nanoparticles to modify macrophages, IL-10 se-
cretion was measured from LPS activated macrophages. Two studies were performed
to evaluate whether NPs could mitigate LPS mediated activation or prevent acti-
vation of macrophages by LPS. LPS classically activates J774A.1 monocytes to M1
macrophages and moderately increases IL-10 production [41]. On the other hand, IL-
10 production for M2 macrophages would be greatly increased [42]. In both studies,
IL-10 production was measured with ELISA. In order to understand production on a
per cell basis, cell nuclei were counter-stained with DAPI and counted from confocal
images.
The first study was performed to evaluate whether NPs could mitigate LPS me-
diated activation. The ability to repolarize or reduce further activation could be
beneficial for treating inflammatory diseases, since repolarization or a reduction of
M1 macrophages should reduce pro-inflammatory cytokines. The reduction of pro-
inflammatory cytokines should reduce inflammation which would be beneficial for
healing the inflammation site. As such, cells were initially activated by LPS, followed
by administration of either soluble dextran sulfate, dextran sulfate-coated NPs, or
no materials. Exact treatment times are shown in the timeline in Figure 4.13A.
At the time aliquots were taken, each group had similar cell densities, suggesting
soluble DS and DS-coated NPs did not have an effect on cell proliferation when
treated after activation. Soluble dextran sulfate significantly decreased IL-10 con-
centration/production both on the basis of concentration (Figure 4.13B) and cell
count (Figure 4.13C)). Administration of NPs caused a moderate, but not statisti-
cally significant, decrease in IL-10 production. As such, soluble DS seemed capable
of shifting phenotype activation, while the nanoparticles cannot. These results were
different from that reported in the literature. For example, Kono et al. demonstrated
soluble dextran sulfate decrease IL-12 production while increasing IL-10 production
of mouse peritoneal macrophages [43]. In addition to the difference in cell sources, it
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was likely that the timing of material addition and the concentration of LPS used to
activate macrophage were different. Specifically, Kono et al. activated macrophages
with 10 ng/mL LPS at the same time as dextran sulfate administration, while this
study activated macrophages with 1 µg/mL LPS for 24 hours prior to administra-
tion of dextran sulfate or dextran sulfate coated NPs. While further studies are
required to clarify the influence of dextran sulfate (soluble or NP form) on activated
macrophages, this study has demonstrated that the DS coated NPs were potentially
capable of shifting macrophage phenotype.
Fig. 4.13: A) Treatment timeline for testing the effect of NPs on LPS treated cells.
B) Measurement of IL-10 production from cells treated with LPS followed by NPs
(n=5). C) Measurement of IL-10 production per cell, from cells treated with LPS
followed by NPs (n=5).
To evaluate whether the NPs could prevent activation of macrophage by LPS, a
second study was performed on cells treated with first NPs followed by LPS. Prevent-
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ing activation could be useful in situations where a medical procedure could induce
unwanted macrophage activation, such as administrion of a stent. As such, cells were
initially treated with either no materials, soluble dextran sulfate, or dextran sulfate
coated NPs for four hours. From NP uptake studies performed earlier, four hours
was adequate for NP uptake by naive J774A.1 monocytes. Figure 4.14A outlines the
experimental timeline. As shown in Figure 4.14B, soluble DS treatment led to slight
increase in IL-10 concentration/production. When IL-10 production was normalized
to cell count (Figure 4.14C), DS-coated NPs decreased IL-10 production on a per cell
basis. However, there was no statistical significance in the difference between all three
groups. Cells were seeded at the same density, however the density after treatment
was higher for both soluble DS and DS coated NPs (Figure 4.14C). The increased cell
density suggests NPs promoted proliferation. The decrease in IL-10 production for
DS coated NP group suggests that there is possibly an inhibitory effect of the NPs
to LPS activation. Additional experiments are required to elucidate whether the DS
coated NPs decrease macrophage activation by LPS.
As stated previously, the NP treatment time of the second study on macrophage
activation was 4 hours, as opposed to the 24 hour treatment of the the first study. The
four hour time was adequate to have considerable uptake by DS coated NPs, while
the short timeframe may have been inadequate for soluble DS uptake. Therefore the
NPs likely facilitated DS uptake by macrophages, allowing for a larger amount a DS
to be uptaken in a shorter time (Figure C.1). A 24 hour treatment time for soluble DS
could possibly lead to more uptake and a similar inhibition of macrophage activation.
Nonetheless, further testing are required to examine this hypothesis.
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Fig. 4.14: A) Treatment timeline for testing the effect of LPS on NP treated cells.
B) Measurement of IL-10 production from cells treated with NPs followed by LPS
(n=4). C) Measurement of IL-10 production per cell, from cells treated with NPs
followed by LPS (n=4) (p=0.063 NP DS v DS). Cell count per plate (in thousands)
above respective group.
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CHAPTER 5. SUMMARY & RECOMMENDATIONS
5.1 Summary
In summary, a modular nanoparticle system was developed to provide tunable sur-
face modification and selective cell targeting. Specifically, a pulse sonication protocol
was established for forming core-shell heparin/PLL nanoparticles whose surface could
be modularly coated with heparin, (m)Tz-heparin, or dextran sulfate. Uniquely, the
introduction of (m)Tz motif on nanoparticle surface permitted facile conjugation of
inert polymer or bioactive ligand via norbornene-tetrazine click reaction. To demon-
strate the modularity of NP surface modification, nanoparticles were PEGylated to
reduce macrophage uptake. On the other hand, a cell adhesive peptide RGDS was
clicked to the NP surface to enhance cellular uptake and recognition. Furthermore,
coating NP surface with dextran sulfate effectively altered the cellular selectivity of
the NP and cytokine production. Overall, this work demonstrates the versatility of
the modular NP system.
5.2 Recommendations
The study designed to determine whether nanoparticles could prevent activation
of macrophages did not clarify whether dextran sulfate-coated NPs inhibited LPS
activation of macrophages. Thus, future studies with adjustments to the testing
parameters are recommended. Additionally, testing secretion of other cytokines, such
as IL-6, IL-12, or TNF-α, should be measured to compliment the finding from the IL-
10 production. NP uptake was suspected to be the cause of the difference between the
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moderate inhibitory effect of the DS-coated NPs and the soluble DS. Thus, a 24-hour
pretreatment with NPs and soluble DS should provide clarity on whether soluble DS
will act in a similar fashion. Another method to clarify the cause of the difference in
activation inhibition will be to compare uptake capabilities of fluorescent-labeled DS
and fluorescent DS-coated NPs.
Modulating cell localization of NPs with RGDS surface modification was not suc-
cessful, possibly due to non-specific binding of heparin to the fibroblast cell surface.
As such, the use of a bio-inert polyanion, could reduce non-specific binding, allowing
for modulation of cell localization with RGDS surface modification.
Even though NPs prepped by two-step pulse sonication demonstrated easy mod-
ification, the Tz-heparin coated NPs were not used for a specific application. Future
studies can delve into using NPs as biomarkers or drug carriers. The ease of modifi-
cation should allow for tagging NPs with a variety of antibodies, for labeling and for
targeted delivery to a variety of cell types.
Finally, future studies may utilize heparin’s ability to bind to proteins, enzymes,
or growth factors. This material characteristic should be beneficial for sequestration
and sustained release of growth factors for promoting tissue regeneration.
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APPENDIX A. REPORTED NP CHARACTERISTICS
Table A.1: Table of Material Characteristics, NP Mixing Method, and Reported
Size of Hep/PLL PEC NPs [11–17].
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APPENDIX B. ADDITIONAL NP CHARACTERIZATION
Table B.1: NPs Prepared with Different Concentrations.
Table B.2: DLS Measurements of 2 Step NPs with Different Layered Polyanions.
PLL concetration of 0.250 mg/mL.
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APPENDIX C. CELLULAR UPTAKE
Fig. C.1: Schematic representation of cellular uptake of (A) DS coated NPs and (B)
soluble DS. Soluble DS shown in black. Soluble PLL and Hep are not included.
